HUMAN PAPILOMAVIRUS: IMMUNE RESPONSE TO INFECTION AND
HUMAN PAPILOMAVIRUS; IMMUNITY; INFECTION; VACCINATION
Interest in immunoglobulin G / A (IgG / IgA) antibodies has greatly increased since human papillomavirus (HPV) vaccines became available worldwide. The objectives of the studies were to describe the course of the IgG / IgA immune response in women immunized with divalent vaccine and those infected with HPV and to describe the course of IgG / IgA responses in cervical and serum secretions one year after the first dose of the vaccine. intramuscular administration of the adjuvant vaccine HPV16 / 18 AS04. Serum and cervical mucus samples were collected for detection of anti-HPV / VLP IgG / IgA by enzyme linked immunosorbent assay (ELISA). The results found show that anti-HPV-VLP IgG in immunized serum was higher (p <0.01), while anti-HPV-VLP-IgA was detected in cervical mucus of virus-infected (p <0.01). Detection of serum antibodies coincides with the induction of high levels of post-vaccine IgG antibodies. IgA antibodies in unvaccinated women were characterized as a possible transudation of the systemic circulation to the cervical mucosa. IgG is a long-term response to any viral infection; thus, anti-HPV-VLPIgG proves the efficacy of the divalent vaccine in protecting against HPV infection. We also observed that immune responses were significant one year after immunization but decreased in cervical and serum samples when compared to levels observed one month after the last dose. This suggests that a vaccine booster may be required to increase antibody titers.